PALI - Palisade Bio Inc

PALI - Palisade Bio Inc

https://www.palisadebio.com

Recent News

Powered by Alpha Vantage

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease ( FSCD )

GlobeNewswire • 1 week, 3 days ago • score: 0.17

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies ...

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

GlobeNewswire • 3 weeks ago • score: 0.28

- Moderated discussion with leading expert in Fibrostenotic Crohn's Disease ( FSCD ) and Inflammatory Bowel Diseases ( IBD ) , Dr. Brian Feagan ...

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

GlobeNewswire • 1 month, 1 week ago • score: 0.20

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events ...

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

GlobeNewswire • 1 month, 2 weeks ago • score: 0.35

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's disease ( FSCD ) and ulcerative colitis ( UC ) , to address significant unmet medical needs Inflammatory Bowel Disease is a large and growing market opportunity in China, with ...

Palisade Bio Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

GlobeNewswire • 1 month, 3 weeks ago • score: 0.30

- Video webcast now available ...

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

GlobeNewswire • 2 months ago • score: 0.23

Veteran clinical leader with successful track record and experience to help guide the Company's clinical strategy in Fibrostenotic Crohn's Disease and Ulcerative Colitis ...

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Business Insider • 5 months ago • score: 0.14

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of ...

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week ( DDW ) 2025

GlobeNewswire • 6 months ago • score: 0.19

PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top 10% of all AGA Abstracts Selected for Poster Presentation at ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. The company is headquartered in Carlsbad, California.

52W High

$4.32

52W Low

$0.59

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.39

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.57

EV/Revenue (<3 favorable)

234.89

P/S (TTM) (<3 favorable)

14.03

P/B (<3 favorable)

2.23

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.24%

Institutions (25–75% balanced)

5.92%

Shares Outstanding

9,119,200

Float

8,618,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-3.64

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.89%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—